GLMDGalmed Pharmaceuticals Ltd.(GLMD)Stock Analysis

AI analysis on 2,800+ stocks →
HealthcareNasdaq
Institutional-grade research for retail investors
SEC EDGAR: CIK 1595353GLMD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

GLMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Galmed Pharmaceuticals Ltd. (GLMD), a Healthcare sector company. GLMD is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.0m in revenue. Based on the latest XBRL financial filings (Q4 2025), Galmed Pharmaceuticals Ltd. reports net income of $-4.8M, free cash flow of $-1.9M. Top institutional holders of GLMD by reported 13-F value include TWO SIGMA INVESTMENTS,, XTX Topco Ltd, JANE STREET GROUP,, based on the most recent SEC filings. GLMD trades on the Nasdaq exchange and files with the SEC under CIK 1595353. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GLMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Galmed Pharmaceuticals Ltd. directly from SEC EDGAR.

Net Income

Q4 2025

$-4.8M

Free Cash Flow

Q4 2025

$-1.9M

Get alerted when GLMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Galmed Pharmaceuticals Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of GLMD

Put GLMD on your watchlist

Track score changes the day Galmed Pharmaceuticals Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is GLMD a good stock to buy?

13F Pro's AI-powered analysis of Galmed Pharmaceuticals Ltd. (GLMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GLMD are available on the GLMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GLMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GLMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Galmed Pharmaceuticals Ltd.'s investment landscape.